Annals of the New York Academy of Sciences, Sept, 2011, Vol.1232, p.376(5)
To authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1749-6632.2011.06063.x Byline: Melissa P Upton (1), Rish K. Pai (2), Michael Vieth (3), Helmut Neumann (4), Cord Langner (5) Keywords: Barrett's esophagus; goblet cells; practice guidelines; stem cells; biopsy strategy; progression; dysplasia; early detection research network; aneuploidy; p53; metaplasia; bone marrow; cancer stimulating cells Abstract: The following on esophageal disease and pathology contains commentaries on the varied definitions of Barrett's esophagus (BE); the optimal biopsy strategy in BE; reliable biomarkers for progression to neoplasia in BE; and the role of bone marrow stem cells in the morphogenesis of Barrett's esophagus. Author Affiliation: (1)Rodger C. Haggitt Gastrointestinal and Hepatic Pathology Service, University of Washington, Seattle, Washington. (2)Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio. (3)Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany. (4)Medical Clinic I, University of Erlangen, Erlangen, Germany. (5)Institute of Pathology, Medical University Graz, Graz, Austria
Cancer Research ; Tumor Proteins ; Multiple Myeloma ; Dysplasia ; Stem Cells ; Stem Cell Research ; Barrett Esophagus
Cengage Learning, Inc.